Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million
26/08/2026 07:53
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million Aug 26 (Reuters) - Biohaven BHVN.N has entered into a licensing agreement with South Korean drug maker SK Biopharmaceuticals 326030.KS for Biohaven's epilepsy drug platform, including Opakalim, for up to $795 million, the companies said in a statement on Wednesday.
(Reporting by Anusha Shah in Bengaluru; Editing by Sonia Cheema)
Recent news on Biohaven
See all newsBrief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
U.S. STOCKS ON THE MOVE-Macy's, American Eagle, Designer Brands